In an allogeneic transplant, the patient receives bone marrow or peripheral blood stem cells from another person -- usually a sibling, but sometimes an unrelated donor.
High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells Subsequent Edition by James O. Armitage (Editor), Karen H. Antman (Editor) This work addresses the issues of treating patients with cancer with higher doses of chemotherapy, whether supported by allogeneic bone marrow transplantation, growth factor support, or no extra treatment. Dose intensive therapy is one of the fastest growing and most promising areas of oncology. This text explores this modality for the broad range of…
Dr. Frederick Locke is a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center and an assistant professor of oncology at the University of South Florida. Dr. Locke’s research interests include autologous and allogeneic hematopoietic stem cell transplantation for lymphoma and myeloma and post-transplant immunotherapy.
Craig Hofmeister describes what allogeneic transplant is, the challenges and the hope to improve this medical procedure moving forward.
Dr. Jose Ochoa-Bayona is a medical oncologist in the Blood and Marrow Transplant Department at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences and the Department of Internal Medicine at the University of South Florida.Dr. Ochoa-Bayona’s research interest includes early phase clinical trials of autologous and allogeneic stem cell transplantation and post-transplant immunotherapy for multiple myeloma.
Dr. Teresa Field is a hematologist in the Department of Blood and Marrow Transplantation at Moffitt Cancer Center and an associate professor of medicine and oncology at the University of South Florida. Dr. Field’s clinical and research interests include clinical outcomes in allogeneic transplantation using alternative donors, novel induction regimes and new methods for treating and preventing graft-versus host disease.